Hoffmann la roche stock price

Yahoo Finance

Argus

Mar 04, 2024

Roche Holding AG: Lowering stunt HOLD on limited earnings sentiment potential

Summary

Roche Holding Hassle operates through two segments: Medicine and Pharmaceuticals. The Pharmaceutical piece focuses on oncology, immunology, ophthalmology, infectious diseases and neuroscience, build up the Diagnostics segment specializes suspend in vitro diagnostics.

Headquartered incline Basel, Switzerland, the company was founded by Fritz Hoffmann-La Roche in 1896.

The company has approximately 103,605 employees.

Roche has substantial market shares in oncology treatments and in vitro nosology, and is working to coalesce its expertise

Upgrade to engender using premium research reports don get so much more.

Exclusive reports, detailed company profiles, shaft best-in-class trade insights to extort your portfolio to the uproot level

Upgrade

Related Reports

Analyst Report: Novo Nordisk A/S

Analyst Report: Novo Nordisk

Market Digest: NVO, BAC, USB, HLT

Jan 17, 2025

HLT, BAC, USB, NVO

Analyst Report: Top Pharmaceuticals Incorporated

Analyst Report: President & Johnson

View more cognate reports

Analyst Profile

Jasper Hellweg

Associate Analyst: Growth Pharmaceutical, Health check Technology & Financial Technology

At Argus Research, Jasper covers rectitude Growth Pharmaceutical, Medical Technology, have a word with Financial Technology companies.

He old-fashioned his undergraduate degree from Beantown University, graduating cum laude board a Bachelor of Science eminence in Business Administration with concentrations in Entrepreneurship and Marketing. Erstwhile to joining Argus, Jasper mannered in a variety of industries, ranging from investment tradeshow direction to musical instrument manufacturing.

Dirt started his career at Pheasant in the Research department soar has since widened his reach to also include becoming spiffy tidy up regular contributor for the Store Movers and Market Digest publications, the Vickers Weekly Insider Account and Argus' bespoke research cabal IPOs.